Author:
Asaumi Ryuta,Sugano Kiyohiko
Publisher
Springer International Publishing
Reference60 articles.
1. Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I (2019) Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther 105:899–911
2. Krishnaswami S, Austin D, Pasqua OD, Gastonguay MR, Gobburu J, van der Graaf PH et al (2020) MID3: mission impossible or model-informed drug discovery and development? Point-counterpoint discussions on key challenges. Clin Pharmacol Ther 107:762–772
3. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ et al (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89:259–267
4. Jamei M, Dickinson GL, Rostami-Hodjegan A (2009) A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up’ vs ‘top-down’ recognition of covariates. Drug Metab Pharmacokinet 24:53–75
5. Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM et al (2020) Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 submissions to the US FDA’s office of clinical pharmacology. J Clin Pharmacol 60(Suppl 1):S160–S178